Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)
Pfizer doles out $2.3B for blood cancer player to flesh out its end-of-decade oncology portfolio
As its Covid-19 vaccine rakes in cash, Pfizer is in a position to move boldly as it looks at the hazy end of the current …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
